CAM
SGNT

Capstone Asset Management’s SAGENT PHARMACEUTICALS INC COM STK (DE) SGNT Stock Holding History

Capstone Asset Management’s Portfolio SGNT Stock Details SGNT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q2 		– Sell
-10,810
Closed -$251K – 1669
2015
Q1 		$251K Buy
10,810
+1,060
+11% +$28.1K 0.01% 1478
2014
Q4 		$245K Sell
9,750
-410
-4% -$12K 0.01% 1485
2014
Q3 		$316K Buy
+10,160
New +$275K 0.01% 1314

Other funds holding SGNT

Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PCM
Penn Capital Management Philadelphia, Pennsylvania $1.29B AUM 53.44% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
RIM
Ranger Investment Management Dallas, Texas $1.38B AUM 24.55% 1-Year Est. Return
HM
HealthCor Management New York $109M AUM 10.64% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Capstone Asset Management's SGNT Position: Q2 2015 in Review

Capstone Asset Management sold out of SAGENT PHARMACEUTICALS INC COM STK (DE) (SGNT) in Q2 2015, closing a stake of 10,810 shares — an estimated $251K sold.

Capstone Asset Management first reported a position in SGNT in Q3 2014 and held it in 3 quarters. The position peaked at $316K in Q3 2014. 136 funds tracked by Wall St. Rank hold SGNT as of Q2 2015.

  • Capstone Asset Management reported no remaining SAGENT PHARMACEUTICALS INC COM STK (DE) position as of Q2 2015 after selling out during the quarter.
  • Capstone Asset Management sold 10,810 SAGENT PHARMACEUTICALS INC COM STK (DE) shares in Q2 2015, an estimated $251K.
  • Capstone Asset Management first reported a position in SAGENT PHARMACEUTICALS INC COM STK (DE) in Q3 2014 and held it in 3 quarters.
  • Capstone Asset Management's SAGENT PHARMACEUTICALS INC COM STK (DE) position peaked at $316K in Q3 2014.
  • 136 funds tracked by Wall St. Rank held SAGENT PHARMACEUTICALS INC COM STK (DE) as of Q2 2015.

Based on Capstone Asset Management's 13F filing for Q2 2015, filed 15 Jul 2015.